JP2023536630A5 - - Google Patents
Info
- Publication number
- JP2023536630A5 JP2023536630A5 JP2023507633A JP2023507633A JP2023536630A5 JP 2023536630 A5 JP2023536630 A5 JP 2023536630A5 JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023536630 A5 JP2023536630 A5 JP 2023536630A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061109P | 2020-08-04 | 2020-08-04 | |
| US63/061,109 | 2020-08-04 | ||
| PCT/US2021/044330 WO2022031695A1 (en) | 2020-08-04 | 2021-08-03 | Pd-l1 binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536630A JP2023536630A (ja) | 2023-08-28 |
| JP2023536630A5 true JP2023536630A5 (https=) | 2024-08-08 |
| JP7854423B2 JP7854423B2 (ja) | 2026-05-01 |
Family
ID=80118473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507633A Active JP7854423B2 (ja) | 2020-08-04 | 2021-08-03 | Ｐｄ－ｌ１結合性作用剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230303699A1 (https=) |
| EP (1) | EP4192884A4 (https=) |
| JP (1) | JP7854423B2 (https=) |
| CN (1) | CN116390951A (https=) |
| AU (1) | AU2021322183A1 (https=) |
| CA (1) | CA3187850A1 (https=) |
| WO (1) | WO2022031695A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116390939A (zh) * | 2020-08-04 | 2023-07-04 | 埃克塞里艾克西斯公司 | 多重特异性结合剂及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362325B2 (en) * | 2007-10-03 | 2013-01-29 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics |
| PE20110385A1 (es) * | 2008-07-18 | 2011-06-22 | Bristol Myers Squibb Co | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 |
| BR112014002716A2 (pt) * | 2011-08-05 | 2017-06-13 | Genentech Inc | anticorpos anti-poliubiquitina e métodos de uso |
| MA40513A (fr) * | 2014-08-12 | 2017-06-21 | Novartis Ag | Conjugués médicament-anticorps anti-cdh6 |
| CA3007135A1 (en) * | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| US20190106494A1 (en) * | 2016-06-13 | 2019-04-11 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018005682A2 (en) | 2016-06-29 | 2018-01-04 | Checkpoint Therapeutics, Inc. | Pd-l1-specific antibodies and methods of using the same |
| DK3592769T3 (da) | 2017-03-09 | 2024-08-12 | Genmab As | Antistoffer mod pd-l1 |
| SG10202110182PA (en) * | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| EP3612565A4 (en) | 2017-04-18 | 2021-06-16 | R-Pharm Overseas, Inc. | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
| US20210363265A1 (en) * | 2017-08-24 | 2021-11-25 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs |
| CA3080120C (en) * | 2017-10-27 | 2023-11-21 | New York University | Anti-galectin-9 antibodies and uses thereof |
| EP3732203A4 (en) * | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1 |
| CA3095076A1 (en) | 2018-03-29 | 2019-10-03 | Adagene Inc. | Anti-pd-l1 antibodies and use thereof |
-
2021
- 2021-08-03 US US18/018,863 patent/US20230303699A1/en active Pending
- 2021-08-03 CN CN202180067676.0A patent/CN116390951A/zh active Pending
- 2021-08-03 CA CA3187850A patent/CA3187850A1/en active Pending
- 2021-08-03 JP JP2023507633A patent/JP7854423B2/ja active Active
- 2021-08-03 WO PCT/US2021/044330 patent/WO2022031695A1/en not_active Ceased
- 2021-08-03 EP EP21853864.3A patent/EP4192884A4/en active Pending
- 2021-08-03 AU AU2021322183A patent/AU2021322183A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP2017535257A5 (https=) | ||
| AU2019412754B2 (en) | BTN3A binding proteins and uses thereof | |
| CA3144324A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen | |
| JP2023549537A5 (https=) | ||
| CN113874399A (zh) | 抗ror1/抗cd3双特异性结合分子 | |
| CN114502591A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2023536631A5 (https=) | ||
| JP2024532489A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| JP2017507131A5 (https=) | ||
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| JP2016501877A5 (https=) | ||
| JP2025506143A5 (https=) | ||
| CN110461874B (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
| CN115916816A (zh) | 抗血清白蛋白抗体 | |
| JP2024517953A5 (https=) | ||
| JP2022517216A5 (https=) | ||
| TW202204424A (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| JP2023536630A5 (https=) | ||
| JP2022502079A5 (https=) |